SciELO - Scientific Electronic Library Online

 
vol.24 issue2Hospitalizaciones por reacciones adversas a medicamentos y abandono del tratamiento farmacológico en el hospital universitarioFactores de riesgo para aterosclerosis en enfermedades autoinmunitarias author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Médica del Uruguay

On-line version ISSN 1688-0390

Abstract

DANZA, Álvaro; CRISTIANI, Federico  and  TAMOSIUNAS, Gustavo. Trimetazidina en el tratamiento del angor estable. Rev. Méd. Urug. [online]. 2008, vol.24, n.2, pp.109-117. ISSN 1688-0390.

Summary Introduction: ischaemic cardipathy is a highly prevalent disease in our country. It is caused by an imbalance between the oxygen requirement of the myocardium and the oxygen supplied to it. Conventional therapeutics focuses on modification of hemodynamics variables . However, a significant number of patients still evidenced symptoms after applying these therapeutics. Thus, new ways of drug (non-hemodynamic) interventions are being sought, such as metabolic kinds of intervention, by increasing myocardial energy substrates yield. Trimetazidine is a drug that acts by modulating myocardial metabolism, proving to be a new and promising action mechanism. Objective: to update and perform a critical analysis of the information on the efficacy and safety of trimetazidine in treating stable angina pectoris that is currently available, thus learning about its usefulness in clinical practice and encouraging its rational use. Method: Medline, Lilacs and Cochrane Databases were searched, looking for information. To learn about its efficacy, controlled clinical trials, systematic reviews and meta-analysis were included. To learn about safety, notifications, series of cases and drug surveillance bulletins were also integrated. Results: studies conducted showed symptomatic improvement with trimetazidine, with no notifications of serious adverse effects, although elderly patients evidenced extrapyramidal symptoms. Conclusions: trimetazidine has been shown to improve symptoms in patients with stable angina pectoris. There is no information about its effects on "hard" variables such as mortality or myocardial infarction. As with all new drugs, active safety surveillance is advised.

Keywords : ANGINA PECTORIS [ terapia]; TRIMETAZIDINA [uso terapéutico]; EVALUACION DE MEDICAMENTOS; ANGINA PECTORIS [ therapy]; TRIMETAZIDINE [ therapeutic use]; DRUG EVALUATION.

        · abstract in Spanish | French | Portuguese     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License